Investors: News
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose - - Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD dosing cohorts in which...
Moleculin to Present at the H.C. Wainwright Global Investment Conference
HOUSTON, May 19, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
- Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies - - Multiple key clinical and regulatory milestones expected throughout 2022 - - Company has sufficient capital to fund operations into 2024 -...
Moleculin Receives Approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence imminently - HOUSTON, May 10, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or...
Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
- Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine - Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine combined compared...
Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer
Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomas Company continues to advance clinical development across...
Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
Investigational New Drug (IND) application clearance from FDA opens up potential for additional investigator funded and led clinical studies HOUSTON, April 21, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Announces Corporate Rebranding and Launch of New Website
Company reiterates commitment to solving some of the toughest challenges in highly resistant cancers and viruses and developing better treatments that can make a real impact in people's lives HOUSTON, April 14, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
/C O R R E C T I O N — Moleculin Biotech, Inc./
In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised by the company that the second paragraph following the details...
Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting
Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients HOUSTON, April 8, 2022...